Posters
LAG-3 expression by RNA next-generation sequencing: Comparison with LAG-3 immunohistochemistry in melanoma
17 Nov 2023
The use of LAG-3 expression as a clinical biomarker to select for patients who might benefit from anti-LAG-3 immuniotherapies might require multiple rapid, sensitive, and accurate assays. In this study, LAG-3 status by RNA-seq and immunohistochemistry (IHC) in melanoma were significantly correlated, but further research is required to establish RNA-seq cutoffs in larger and more diverse patient cohorts.
- Sarabjot Pabla
- Lori Johnson
- Jeffrey Shuster
- R. J. Seager
- Erik Van Roey
- Shuang Gao
- Maria-Fernanda Senosain
- Stephanie B. Hastings
- Paul DePietro
- Shengle Zhang
- Kyle C. Strickland
- Jeffrey M. Conroy
- Taylor J. Jensen
- Marcia Eisenberg
- Eric A. Severson
- Shakti Ramkissoon